<DOC>
	<DOCNO>NCT00929591</DOCNO>
	<brief_summary>RATIONALE : Estrogen cause growth breast cancer cell . Hormone therapy use tamoxifen may fight breast cancer block use estrogen tumor cell . Drugs use chemotherapy , doxorubicin , cyclophosphamide , fluorouracil , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether give tamoxifen alone effective treat breast cancer give tamoxifen together chemotherapy chemotherapy . PURPOSE : This randomized phase III trial study give tamoxifen without combination chemotherapy compare well work treat postmenopausal woman undergone surgery breast cancer .</brief_summary>
	<brief_title>SWOG-8814 Tamoxifen With Without Combination Chemotherapy Postmenopausal Women Who Have Undergone Surgery Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare disease-free survival overall survival postmenopausal woman node-positive , estrogen and/or progesterone receptor-positive adenocarcinoma breast randomly assign postoperative adjuvant treatment long-term ( 5 year ) tamoxifen vs. CAF ( cyclophosphamide/doxorubicin/fluorouracil ) plus concurrent long-term tamoxifen vs. CAF follow long-term tamoxifen . II . Compare relative toxicity three regimen . OUTLINE : Randomized study . All patient randomize Arms I , II , III . Lumpectomy patient must receive radiotherapy Regimen A . At discretion physician , mastectomy patient may receive radiotherapy Regimen B tumor great 5 cm diameter , 4 positive node , extranodal extension tumor axillary fat . Patients randomized Arm I receive radiotherapy begin soon feasible postoperatively ; patient may irradiate receive tamoxifen . Patients Arms II III receive radiotherapy treat either postoperatively prior registration completion recovery 6 course CAF . Arm I : Antiestrogen Therapy . Tamoxifen , TMX , NSC-180973 . Arm II : 3-Drug Combination Chemotherapy follow Antiestrogen Therapy . CAF : Cyclophosphamide , CTX , NSC-26271 ; Doxorubicin , DOX , NSC-123127 ; Fluorouracil , 5-FU , NSC-19893 ; follow TMX . Arm III : 3-Drug Combination Chemotherapy plus Concurrent Antiestrogen Therapy . CAF ; plus concurrent TMX . Regimen A : Radiotherapy . Irradiation breast underlie chest wall ( optionally ) supraclavicular area , indicate , axilla , use megavoltage equipment photon energies 6 MV follow , indicate , tumor bed boost use either electron iridium-192 ( 192-Ir ) implant . Regimen B : Radiotherapy . Irradiation chest wall use either megavoltage photon via tangential field electron via direct field plus ( optional ) photon irradiation supraclavicular area , indicate , axilla . PROJECTED ACCRUAL : 350 patient randomized Arm I 530 patient randomize Arms II III . Accrual complete 4 year , 4 additional year require follow-up .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma breast No apocrine , adenoidcystic , squamous carcinoma sarcoma Pathologic Stage T13a , pathologic N12 ( clinical N01 ) , M0 : Rendered free gross tumor surgery Primary tumor movable respect chest wall Axillary node movable respect chest wall No preoperative edema arm , peau d'orange , skin ulceration , inflammatory lesion One positive lymph node require No positive deep mastectomy margin clinical skin involvement ( focal microscopic dermal invasion focal microscopic dermal lymphatic involvement allow ) No evidence metastatic disease pretherapy study ( include chest xray , bone scan , mammogram ) No bilateral invasive tumor Patients noninvasive ductal carcinoma situ opposite breast underwent prophylactic contralateral mastectomy eligible Hormone receptor status : Positive estrogen and/or progesterone receptor ( least 10 fmol/mg protein unequivocally positive immunocytochemical assay one ) Participation SWOG8854 ( flow cytometry ) recommend PATIENT CHARACTERISTICS : Age : Any age Sex : Females Menopausal status : Postmenopausal define 1 following : Bilateral oophorectomy least 2 month prior diagnosis breast cancer ( without estrogen therapy follow surgery ) Prior hysterectomy least 1 ovary remain either 60 year old postmenopausal FSH level Natural menopause ( last menstrual period least 1 year prior registration 412 month prior registration postmenopausal FSH level ) Treated postmenopausal estrogen therapy either 55 year old postmenopausal FSH level Performance status : Not specify Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin 1.2 x normal Alkaline phosphatase 1.2 x normal SGOT SGPT 1.2 x normal Renal : Creatinine 2.0 mg/dL Cardiovascular : No uncontrolled hypertension No history ischemic heart disease CHF Normal ejection fraction MUGA ( require deem clinically necessary assessment ) Other : No medical condition would preclude protocol therapy : No severe diabetes No active ulcer disease No significant psychiatric disease No second malignancy within 5 year except : Adequately treat nonmelanomatous skin cancer Curatively treat Stage I cervical carcinoma Pretreatment mammogram chest xray complete 3 month preoperatively ; blood/body fluid analyse determine eligibility complete within 14 day prior registration ; prestudy bone scan complete within 12 week prior registration and/or within 4 week prior surgery PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : No prior hormonal therapy ( except 14 day tamoxifen stop prior registration ) Prior estrogen and/or progesteronecontaining hormone preparation nononcologic therapy allow , must discontinue prior registration Postmenopausal estrogen therapy discontinue patient time diagnosis breast cancer Radiotherapy : Postoperative chest wall and/or regional lymph node irradiation allow mastectomy patient ( discretion physician ) either prior registration protocol follow : Tumor great 5 cm diameter 4 positive node Extranodal extension tumor axillary fat No radiotherapy reason mastectomy patient Postoperative radiotherapy either prior registration , tamoxifen , completion chemotherapy require lumpectomy patient Radiotherapy must complete ( give chemotherapy ) prior registration No immediate radiotherapy randomization chemotherapy Surgery : Radical , modified radical , breastsparing surgical procedure least level I II axillary dissection analysis least 6 node require within 12 week prior registration Lumpectomy must include : Total excisional biopsy rim normal breast tissue Microscopically negative margin Level I II axillary dissection Tumor 5 cm great diameter Clinical mammographic examination demonstrate absence multicentric lesion Type surgery , number node examine , number positive node , size primary tumor ( size large tumor 1 mass ) must record</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>